

# Advancing Skin Cancer Prevention: Nicotinamide and DNA Repair Enzymes

Eleanor Tung Hahn<sup>1,2\*</sup>, Lauren Moy<sup>2</sup> and Ronald Moy<sup>2</sup>

**Corresponding author:** Eleanor Tung Hahn, Department of Cancer Research, Lake Erie College of Medicine, Bradenton, USA, E-mail: eleanortunghahn@gmail.com  
**Received:** 14-Jun-2023; Manuscript No. AOT-23-102455; **Editor assigned:** 16-Jun-2023, PreQc No. AOT-23-102455 (PQ); **Reviewed:** 03-Jul-2023, QC No. AOT-23-102455; **Revised:** 10-Jul-2023, Manuscript No. AOT-23-102455 (R); **Published:** 18-Jul-2023, DOI: 10.4172/aot.1000228

**Citation:** Hahn ET, Moy L, Moy R (2023) Advancing Skin Cancer Prevention: Nicotinamide and DNA Repair Enzymes. J Oncol Res Treat. 8:228.

**Copyright:** © 2023 Hahn ET, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

Historically, the public has looked to sunscreen as the primary method for prevention of skin cancer. However, fortunately there have been advancements in chemopreventative care for both precancerous lesion progression of Actinic Keratoses (AKs) and Non-Melanoma Skin Cancers (NMSCs) that have potential to be more patient-friendly for consistent at home use. These measures can be adjunctive therapies to daily broad-spectrum sunscreen or as well as in office procedures. As a whole, the advantage of these newer therapeutics is that they have dual mechanisms of action in that they promote repair of past damage and prevent future

incidence of NMSCs by GHÄ over the FG-month survey period, with a specific decrease in basal cell carcinomas in s uamous cell carcinoma by GEÄ and HEÄ respectively žHä. This effect was more pronounced in those participants who had a higher number of prior NMSCs at baseline. Additionally, their study found an overall decrease in the incidence of AKs over the course of the survey period. The mechanism by which nicotinamide is able to exert these anti-neoplastic effects is through prevention of ATÜ depletion and promotion of ÖNA repair in cells that have been damaged by UV rays žHä. Ultraviolet radiation (UVÜ) also leads to immunosuppression in the cell secondary to ÖNA damage. These beneficial effects did not last after treatment was discontinued, which could be slightly disheartening to some patients žHä. Yet, the positive effects while taking the medication are undeniable.

Another exciting chemopreventive class of agents are DNA repair enzymes. They hold particular appeal because they are typically used in topical formulation. When applied to the skin, TI endonuclease (TINÍ), a bacterial ÖNA repair enzyme, can penetrate the stratum corneum and repair ÖNA by removing Cyclobutane Uvrhmidine Öimers (CÜÖs) that are introduced into cells by photo damage žHä. The safety and efficacy of topical TINÍ is well established, with studies dating back to FJÍÍ. In a GEEF study investigating chemoprevention with topical TINÍ in Yeroderma Uigmentosum patients, the rate of new AK formation decreased by 68%, and the rate of BCC development

Researcher posited that since the T4N5 was applied after UV exposure it was a contributor to chemoprevention and could be used at any point after sun exposure and still exert the DNA repair effects [6]. Carducci, et al. built upon this work by investigating the efficacy of sunscreen alone followed by T4N5 application versus a combination product of sunscreen with T4N5 and endonuclease. Their outcomes were in line with the Emanuele, et al. study, confirming that sunscreen with added DNA repair enzymes can significantly prevent progression of precancerous to cancerous lesions (AKs to SCC)[7]. In this study, UV damage was quantified with field cancerization imaging, presence of hyperkeratosis, and amount of CPDs (known target of both T4N5 and photolyase) [7]. In addition to these enzymes, other studies have also included 8-oxoguanine glycosylase 1, an enzyme that reduces the oxidative stress in DNA.

When a topical medication containing T4N5, photolyase, and OGG1 was applied to the skin, it was shown to decrease signs of UV damage (CPDs and expression of p53) [8,9].

## Conclusion

As demonstrated by the studies, some of the genetic targets that contribute to photo-carcinogenesis in the skin have been established. With targeted therapies such as T4N5, photolyase, and OGG1 available to complement traditional prevention methods like sunscreen, there is a greater potential to both actively prevent and reverse malignant changes within the skin. Looking forward, DNA repair enzymes seem to be the future standard of comprehensive UV radiation protection. Researchers are constantly searching for new genetic targets to prevent and further delay the progression of cancerous lesions. New discoveries in this arena already show promise. A recent 2023 article investigating acute UVB associated changes in the skin identified multiple new gene families that show acute up or down-regulation following UV exposure, indicating there are many more potential targets for novel therapeutics as well.

## References

1. Rosenthal A, Stoddard M, Chipps L, Herrmann J (2019) Skin cancer prevention: A Review of current topical options complementary to sunscreens. *J Eur Acad Dermatol Venereol* 33: 1261-1267.
2. Stoddard M, Herrmann J, Moy L, Moy R (2017) Improvement of actinic keratoses using topical DNA repair enzymes: A randomized placebo-controlled trial. *J Drugs Dermatol* 16: 1030-1034.
3. Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziel RA, et al. (2015) A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. *N Engl J Med* 373: 1618-1626.
4. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, et al. (2001) Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: A Randomised study. *Lancet* 357: 926-929.
5. Kabir Y, Seidel R, Mcknight B, Moy R (2015) DNA repair enzymes: An Important role in skin cancer prevention and reversal of photodamage: A review of the literature. *J Drugs Dermatol* 14: 297-303.
6. Emanuele E, Altabas V, Altabas K, Berardesca E (2013) Topical application of preparation M (2001) EMr Nto 8 ap